

individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel "Drug Abuse Prevention Dissemination".

*Date:* April 19, 2000.

*Time:* 11 am to 1 pm.

*Agenda:* To review and evaluate contract proposals.

*Place:* Neuroscience Center, National Institutes of Health, 6001 Executive Blvd., Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547, (301) 435-1439.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: April 13, 2000.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 00-9807 Filed 4-18-00; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* April 19, 2000.

*Time:* 1:30 pm to 2:30 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Joseph Kimm, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5178 MSC 7844, Bethesda, MD 20892, (301) 435-1249.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* April 28, 2000.

*Time:* 1 pm to 2 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* H. Mac Stiles, DDS, PhD, MPH, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7816, Bethesda, MD 20892, 301-435-1785.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* May 1, 2000.

*Time:* 2 pm to 5 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Marcelina B. Powers, DVM, MS, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7804, Bethesda, MD 20892, (301) 435-1720.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* May 3, 2000.

*Time:* 1 pm to 4 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Carl D. Banner, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5212, MSC 7850, Bethesda, MD 20892, (301) 435-1251, [bannerc@drgh.nih.gov](mailto:bannerc@drgh.nih.gov)

*Name of Committee:* Center for Scientific Review Special Emphasis Panel.

*Date:* May 3, 2000.

*Time:* 2 pm to 3 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIH, Rockledge 2, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Marcelina B. Powers, DVM, MS, Scientific Review Administrator, Center for Scientific Review, National

Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7804, Bethesda, MD 20892 (301) 435-1720.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 13, 2000.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 00-9806 Filed 4-18-00; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospect Grant of Exclusive License: Therapeutic and Diagnostic Uses of Novel Thiolesters for HIV and Other Applications

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209 (c)(1) and 37 CFR 404.7 (a) (1) (i) that the National Institutes of Health (NIH), Department of Health and Human Services (DHHS), is contemplating the grant of an exclusive license worldwide to practice the inventions embodied in patents under "Supplementary Information" to Achillion Pharmaceuticals, Inc., having a place of business in New Haven, Connecticut. The patent rights in these inventions have been assigned to the government of the United States of America.

**DATES:** Only written comments and/or license applications which are received by the NIH Office of Technology Transfer on or before June 19, 2000 will be considered.

**ADDRESSES:** Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: Mr. J.P. Kim, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7056, ext. 264; Facsimile: (301) 402-0220. A signed Confidential Disclosure Agreement (CDA) may be required to receive copies of the patent application.

**SUPPLEMENTARY INFORMATION:** The patent applications to be licensed are: "Novel Thiolesters and Uses Thereof", U.S. Provisional Patent Application Serial

No. 60/089,842, filing date 06/19/1998, "Novel Thiolesters and Uses Thereof", PCT International Patent Application No. PCT/US99/13856, International Filing Date 06/18/1999.

The zinc finger has been found in many proteins and in a great variety of species (e.g., the zinc finger structure can be found in the human immunodeficiency virus (HIV)). In viruses, the zinc-binding domains of nucleocapsid proteins have been identified as being involved in both early and late phases of viral replication, thus making them potentially attractive targets for antiviral agents.

The present invention provides for a novel family of thiolesters and uses thereof. These thiolesters are capable of inactivating viruses and other agents by a variety of mechanisms, particularly by complexing with metal ion-complexing zinc fingers. The invention further provides for methods for inactivating a virus, such as HIV, using these compounds, and thereby also inhibiting transmission of the virus.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of novel thiolesters of the invention for therapeutic and diagnostic uses for anti-viral and anti-retroviral (including anti-HIV/AIDS), anti-tumor, anti-parasitic (e.g., malaria), anti-bacterial, and anti-fungal applications, as well as for agricultural uses (e.g., insecticidal use).

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act (FOIA), 5 U.S.C. 552.

Dated: April 13, 2000.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 00-9809 Filed 4-18-00; 8:45 am]

**BILLING CODE 4140-01-PJ**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Public Health Service**

**National Toxicology Program; National Toxicology Program (NTP) Board of Scientific Counselors Technical Reports Review Subcommittee Meeting; Review of Draft NTP Technical Reports**

Pursuant to Public Law 92-463, notice is hereby given of the next meeting of the NTP Board of Scientific Counselors Technical Reports Review Subcommittee on May 18, 2000 in the Rodbell Auditorium, Building 101, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 Alexander Drive, Research Triangle Park, North Carolina. The meeting will begin at 8:30 a.m. on May 18 and is open to the public. The primary agenda topic is the peer review of draft Technical Reports of long-term toxicology and carcinogenesis studies from the NTP. There will also be a presentation about the beneficial effects of the NIH2000 diet in chronic studies.

Tentatively scheduled for peer review on May 18 are draft Technical Reports of six two-year studies, listed alphabetically in the attached table, along with supporting material. Studies were conducted using Fischer 344 rats and/or B6C3F<sub>1</sub> mice. The tentative order of review is given in the far right column of the table.

**Draft Reports Available for Public Review and Comment**

Approximately one month prior to the meeting, the draft reports will be available for public review and comment on the Internet free of charge through the Environmental Health Information Service (EHIS) at <http://ehis.niehs.nih.gov>. Printed copies can be obtained, as available, from: Central Data Management, NIEHS, PO Box 12233 MD E1-02, Research Triangle Park, NC 27709, T: 919-541-3419, FAX: 919-541-3687, or email: [CDM@niehs.nih.gov](mailto:CDM@niehs.nih.gov).

The NTP Board of Scientific Counselors Technical Reports Review Subcommittee meeting is open to the public and public comment on any of the Technical Reports is welcome. Time will be provided for public comment on each of the reports under review. In order to facilitate planning for the meeting, persons requesting time for an oral presentation on a particular Technical Report are asked to notify the Executive Secretary, Dr. Mary S. Wolfe

(PO Box 12233, MD A3-07, Research Triangle Park, NC 27709; telephone 919/541-3971; FAX 919/541-0295; email [wolfe@niehs.nih.gov](mailto:wolfe@niehs.nih.gov)). Persons registering to make comments are asked to provide, if possible, a written copy of their statement by May 12th to enable review by the Subcommittee and staff prior to the meeting. Written statements can supplement and may expand the oral presentation, and each speaker is asked to provide his/her name, affiliation, mailing address, phone, fax, e-mail and supporting organization (if any). At least seven minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes. Registration for making public comments will also be available on-site. If registering on-site to speak and reading oral comments from printed copy, the speaker is asked to bring 25 copies of the text. These copies will be distributed to the Chair and Subcommittee members and supplement the record.

Written comments, in lieu of making oral comments, are also welcome. The comments should include name, affiliation, mailing address, phone, fax, e-mail and sponsoring organization (if any) and preferably be received by May 12th to enable review by the Subcommittee and staff prior to the meeting.

**Request for Additional Information**

The NTP would welcome receiving toxicology and carcinogenesis information from completed, ongoing, or planned studies as well as current production data, human exposure information, and use patterns for any of the chemicals listed in this announcement. Please forward this information to Central Data Management at the address given above who will relay it to the appropriate staff scientist.

The agenda and a roster of Subcommittee members will be available prior to the meeting on the NTP web homepage at <http://ntp-server.niehs.nih.gov> and upon request from the Executive Secretary. Following the meeting, summary minutes will be available on the NTP web homepage and upon request to Dr. Wolfe.

**Attachment**

Dated: April 11, 2000.

**Samuel H. Wilson,**

*Deputy Director, National Institute of Environmental Health Sciences.*